Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal

Search Medical Condition
Please enter condition
Please choose location

Myelofibrosis Clinical Trials

A listing of Myelofibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (38) clinical trials

Study of the JAK Inhibitor INCB018424 tablet administered orally to subjects with primary myelofibrosis, post-polycythemia vera-myelofibrosis or post-essential thrombocythemia-myelofibrosis Patient Inclusion Criteria: 18 + years of age, diagnosis of PMF or PPV-MF, either resistant or refractory to, intolerant of, or in the investigator's opinion not candidates for available therapy, must ...

Phase

People with myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center..

Phase N/A

This is a prospective, longitudinal, non-interventional study in an adult population (age ≥ 18 years) of men and women who have been diagnosed with select subcategories of either MF or ET. Patients will be enrolled over approximately 24 months and observed for a minimum of 36 months from enrollment.

Phase

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populations. TERCIARY OBJECTIVES: I. Describe pharmacodynamics (PD) effects of alisertib in peripheral blood and/or bone marrow samples. II. ...

Phase N/A

Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF) Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Study Drug Administration: If you are found to be eligible to take part in this study, you will take LCL161 by mouth on Days 1, 8, 15, and 22 of each cycle, +/- 3 days. You will fast for 2 hours before and 2 hours after taking LCL161. This means ...

Phase

iCare for Cancer Patients

As part of normal clinical care, subjects will undergo peripheral blood draws and biopsies for disease assessment of their cancer. In cases of hematological malignancies, bone marrow aspiration & biopsy are routinely performed. As part of this project, the following will be done to the samples collected and with clinical ...

Phase N/A